Related Experiment Video
Updated: Feb 11, 2026

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers
Marc Peeters1, Andrés Cervantes2, Shanti Moreno Vera3
1Antwerp University Hospital, Edegem, Belgium.
Abstract:
Fluoropyrimidines are currently the backbone of treatment for gastrointestinal (GI) cancers but development of resistance to these agents remains a major problem. Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer. This article reviews the clinical value of trifluridine/tipiracil as a monotherapy, including recent trials in GI cancers, and the potential benefit of combining it with other agents in patients with GI cancers, including the preclinical rationale for combination therapy and recently completed and ongoing clinical trials. Data gathered so far suggest that trifluridine/tipiracil has the potential to form the chemotherapeutic backbone in the continuum of care for GI cancers in the future.
Related Concept Videos
Applications of GIS: Disaster Management and Emergency Response
Emerging Adulthood
Anatomy of the Gastrointestinal System
Here's a detailed walkthrough of this complex system:
Introduction Cardiac Emergencies
Gastrointestinal Motility Disorders
Histology of the Gastrointestinal (GI) Tract
The mucosa is sometimes called a mucous membrane due to its mucus-secreting features. This membrane is composed of epithelium, which directly interacts with ingested substances, and the lamina propria, a layer...

